|
ERCC2 Asp312Asn, ERCC2 Lys751Gln polymorphisms and potential breast cancer risk factors |
||||||||
| Nonsmokers |
Smokers |
|||||||
|
|
||||||||
| Genotype |
Cases (%) |
Controls (%) |
OR (CI 95%) |
P value |
Cases (%) |
Controls (%) |
OR (CI 95%) |
P value |
|
|
||||||||
| ERCC2 Asp312Asn |
||||||||
| Asp/Asp |
283 (45) |
299 (47) |
1.00 (reference) |
102 (42) |
159 (44) |
1.00 (reference) |
||
| Asp/Asn |
258 (41) |
270 (43) |
1.01 (0.80–1.28) |
111 (46) |
146 (41) |
1.19 (0.83–1.68) |
||
| Asn/Asn |
85 (14) |
64 (10) |
1.4 (0.98–2.02) |
0.16 |
29 (12) |
54 (15) |
0.84 (0.50–1.40) |
0.36 |
|
|
||||||||
| No HRT* users |
HRT users |
|||||||
|
|
||||||||
| Genotype |
Cases (%) |
Controls (%) |
OR (CI 95%) |
P value |
Cases (%) |
Controls (%) |
OR (CI 95%) |
P value |
|
|
||||||||
| ERCC2 Asp312Asn |
||||||||
| Asp/Asp |
175 (46) |
137 (48) |
1.00 (reference) |
75 (40) |
216 (47) |
1.00 (reference) |
||
| Asp/Asn |
152 (40) |
119 (41) |
1.00 (0.72–1.39) |
92 (49) |
191 (42) |
1.39 (0.97–1.99) |
||
| Asn/Asn |
54 (14) |
31 (11) |
1.36 (0.83–2.23) |
0.44 |
19 (10) |
50 (11) |
1.09 (0.61–1.97) |
0.20 |
|
|
||||||||
| No OC** users |
OC users |
|||||||
|
|
||||||||
| Genotype |
Cases (%) |
Controls (%) |
OR (CI 95%) |
P value |
Cases (%) |
Controls (%) |
OR (CI 95%) |
P value |
|
|
||||||||
| ERCC2 Asp312Asn |
||||||||
| Asp/Asp |
240 (46) |
215 (50) |
1.00 (reference) |
143 (42) |
243 (43) |
1.00 (reference) |
||
| Asp/Asn |
208 (40) |
176 (41) |
1.06 (0.81–1.39) |
161 (47) |
242 (43) |
1.13 (0.85–1.51) |
||
| Asn/Asn |
74 (14) |
40 (9) |
1.66 (1.08–2.53) |
0.061 |
40 (12) |
78 (14) |
0.87 (0.56–1.34) |
0.44 |
|
|
||||||||
| ERCC2 Lys751Gln |
||||||||
| Lys/Lys |
79 (15) |
39 (9) |
1.00 (reference) |
38 (11) |
80 (14) |
1.00 (reference) |
||
| Lys/Gln |
223 (43) |
198 (46) |
0.56 (0.36–0.85) |
181 (52) |
248 (44) |
1.54 (1.00–2.36) |
||
| Gln/Gln |
222 (42) |
195 (45) |
0.56 (0.37–0.86) |
0.018 |
127 (37) |
235 (42) |
1.14 (0.73–1.77) |
0.044 |
|
|
||||||||
| Age at first OC use ≤ 23 years |
Age at first OC > 23 years |
|||||||
|
|
||||||||
| Genotype |
Cases (%) |
Controls (%) |
OR (CI 95%) |
P value |
Cases (%) |
Controls (%) |
OR (CI 95%) |
P value |
|
|
||||||||
| ERCC2 Lys751Gln |
||||||||
| Lys/Lys |
23 (14) |
46 (15) |
1.00 (reference) |
15 (8) |
34 (13) |
1.00 (reference) |
||
| Lys/Gln |
80 (50) |
145 (47) |
1.10 (0.62–1.95) |
101 (55) |
103 (40) |
2.22 (1.15–4.29) |
||
| Gln/Gln |
58 (36) |
115 (38) |
1.01 (0.56–1.82) |
0.89 |
69 (37) |
120 (47) |
1.3 (0.66–2.56) |
0.008 |
|
|
||||||||
| Waist-to-hip ratio = 0.85 |
Waist-to-hip ratio > 0.85 |
|||||||
|
|
||||||||
| Genotype |
Cases (%) |
Controls (%) |
OR (CI 95%) |
P value |
Cases (%) |
Controls (%) |
OR (CI 95%) |
P value |
|
|
||||||||
| ERCC2 Asp312Asn |
||||||||
| Asp/Asp |
252 (46) |
356 (46) |
1.00 (reference) |
151 (42) |
102 (48) |
1.00 (reference) |
||
| Asp/Asn |
234 (43) |
326 (42) |
1.01 (0.80–1.28) |
149 (42) |
92 (43) |
1.09 (0.76–1.57) |
||
| Asn/Asn |
60 (11) |
98 (13) |
0.86 (0.60–1.24) |
0.68 |
58 (16) |
20 (9) |
1.96 (1.12–3.43) |
0.06 |
|
* HRT = Hormone Replacement Therapy ** OC = Oral Contraceptive | ||||||||
Bernard-Gallon et al. Molecular Cancer 2008 7:36 doi:10.1186/1476-4598-7-36 |
||||||||